<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04561245</url>
  </required_header>
  <id_info>
    <org_study_id>ALT-801-101</org_study_id>
    <nct_id>NCT04561245</nct_id>
  </id_info>
  <brief_title>ALT-801 in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled Study of Single and Multiple Ascending Doses of ALT-801 in Healthy Overweight and Obese Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Altimmune, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Altimmune, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to assess the safety and tolerability in healthy overweight and&#xD;
      obese volunteers administered single or multiple repeated doses of ALT-801.&#xD;
&#xD;
      This study has 2 parts. Part 1 involves a single dose of ALT-801 taken as a subcutaneous (SC)&#xD;
      injection and will be approximately 36 days in duration. Part 2 involves 12 doses of ALT-801,&#xD;
      once a week for 12 weeks, as a SC injection and will be approximately 116 days in duration.&#xD;
      Each participant will enroll in only one part.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 10, 2020</start_date>
  <completion_date type="Actual">October 23, 2021</completion_date>
  <primary_completion_date type="Actual">October 23, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Number of Participants with One or More Treatment-Emergent Adverse Events (TEAEs)</measure>
    <time_frame>Part 1 SAD Cohorts: up to Day 26; Part 2 MAD Cohorts: up to Day 42</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK): Maximum observed concentration (Cmax) of ALT-801</measure>
    <time_frame>Baseline, Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic (PK): Area Under the Concentration (AUC) vs Time Curve of ALT-801</measure>
    <time_frame>Baseline to Day 26</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacodynamic (PD): Change from baseline in magnetic resonance derived proton density fat fraction (MRI-PDFF)</measure>
    <time_frame>Baseline to Week 6</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>NASH - Nonalcoholic Steatohepatitis</condition>
  <arm_group>
    <arm_group_label>ALT-801 (Part 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of ALT-801 administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part 1)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALT-801 (Part 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating doses of ALT-801 administered once weekly for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered once weekly for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ALT-801</intervention_name>
    <description>Injected subcutaneously (SC)</description>
    <arm_group_label>ALT-801 (Part 1)</arm_group_label>
    <arm_group_label>ALT-801 (Part 2)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Injected subcutaneously (SC)</description>
    <arm_group_label>Placebo (Part 1)</arm_group_label>
    <arm_group_label>Placebo (Part 2)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female healthy volunteers, age 18 to 60 years, inclusive&#xD;
&#xD;
          -  Overweight to obese (BMI 25.0 - 40.0 kg/m2)&#xD;
&#xD;
          -  MRI-PDFF≥ 10% (Part 2 only)&#xD;
&#xD;
          -  Subjects must otherwise be in good general health, with no significant medical&#xD;
             history, have no clinically significant abnormalities on physical examination at&#xD;
             screening, and/or before administration of the initial dose of study medication&#xD;
&#xD;
          -  Ability and willingness to attend the necessary visits to the study center&#xD;
&#xD;
          -  Written informed consent signed prior to entry into the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women who are pregnant or breastfeeding&#xD;
&#xD;
          -  History of diabetes or use of medications for the treatment of diabetes, or&#xD;
             hyperglycemia or HbA1c ≥ 6.5%&#xD;
&#xD;
          -  History of neoplastic disease, or personal or family history of multiple endocrine&#xD;
             neoplasia or medullary cancer of the thyroid, with the following exceptions:&#xD;
&#xD;
               1. Adequately treated non-melanomatous skin carcinoma&#xD;
&#xD;
               2. Female with a history of benign cervical neoplasia if the subject has been&#xD;
                  compliant with surveillance and treatment as recommended by her physician&#xD;
&#xD;
          -  Mentally or legally incapacitated, has significant emotional problems at the time of&#xD;
             screening or expected during the conduct of the study&#xD;
&#xD;
          -  Clinically significant laboratory abnormalities including:&#xD;
&#xD;
             a. Impaired renal function&#xD;
&#xD;
          -  Unlikely to comply with the study protocol or, in the opinion of the Investigator,&#xD;
             would not be a suitable candidate for participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nucleus Networks</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 16, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2020</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NASH</keyword>
  <keyword>Nonalcoholic Steatohepatitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
    <mesh_term>Overweight</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

